

ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH
INVEST & PARTNERING



Cynata Therapeutics Limited

Company Description

Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Cymerus utilises induced pluripotent stem cells (iPSCs) to produce MSCs through a proprietary process that is independent of donor limitations. It and provides an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position. A Phase 1 clinical trial of the Company’s first MSC product is presently underway in graft-versus-host disease. Cynata has a strategic partnership with Fujifilm, which is also the Company’s largest shareholder.


Pipeline and Developments

(see next page)

For more information, please visit www.australiabiotechinvest.com.au



Follow us for the latest event update #AusBioInv



ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH INVEST & PARTNERING



Progress made against business model

Disease target area	External collaborations		Vigorous partner engagement		Further revenues	Key highlights
	Pre-clinical trials started	Proof of concept completed	Deal secured	Clinical trial started	Product in-market	
Graft v Host Disease (GvHD) University of Massachusetts	✓	✓	✓	✓		<ul style="list-style-type: none"> Pre-clinical research with University of Massachusetts show Cymerus MSCs to be highly effective in GvHD Half a billion dollar market by 2021
Asthma Monash University	✓	✓				<ul style="list-style-type: none"> Cymerus MSCs demonstrated significant beneficial effects on three key components of asthma: airway hyper-responsiveness, inflammation and airway remodeling.
ARDS Critical care research group	✓					<ul style="list-style-type: none"> Study to commence to evaluate effectiveness of Cymerus MSCs in sheep with ARDS in association with the Prince Charles Hospital in Brisbane.
Heart attack University of Sydney	✓					<ul style="list-style-type: none"> Pre-clinical trials suggest Cymerus MSCs may have the potential to restore cardiac function and reduce scar size after a heart attack (US\$18.2 billion market by 2019*)
Brain Cancer / Glioblastoma Harvard/BWH	✓					<ul style="list-style-type: none"> Research collaboration in genetically modified MSCs in cancer: involves modifying stem cells to target cancer
Critical Limb Ischemia University of Wisconsin-Madison	✓	✓				<ul style="list-style-type: none"> Pre-clinical study published in peer reviewed journal Cytotherapy, The Journal of Cell Therapy. Study found treatment with MSCs demonstrate beneficial impact on CLI.

Successful outcomes open many other disease targets potentially benefiting from MSC treatment

Note: ARDS – Acute Respiratory Distress Syndrome

Source: 1. <http://gbrresearch.com/media-center/press-releases/cardiovascular-disease-market-us-to-lead-modest-growth-forecasts-gbi-research>

11

What we are looking for:

With Cynata's strategic partnership with Fujifilm (9% shareholder) and leading cell therapy technologies, the Company has generated a growing global awareness of the exciting investment opportunity. We are keen therefore to expand our range of investors to include sophisticated participants in the next value growth cycle for the Company, particularly as we draw closer to completing our current Phase 1 clinical trial.

Contact:

Name: Ross Macdonald
Position: Chief Executive Officer
Company: Cynata Therapeutics Ltd
Address: Level 3, 62 Lygon Street, Carlton 3053, Victoria, Australia
Website: www.cynata.com
Phone: +61 412 119343
Email: ross.macdonald@cynata.com

For more information, please visit www.australiabiotechinvest.com.au

Follow us for the latest event update #AusBioInv